| 000 | 03647 am a22003613u 4500 | ||
|---|---|---|---|
| 042 | _adc | ||
| 100 | 1 | 0 |
_aBjörnsson, Einar S. _eauthor _91853 |
| 700 | 1 | 0 |
_aStephens, Camilla _eauthor _91854 |
| 700 | 1 | 0 |
_aAtallah, Edmond _eauthor _91855 |
| 700 | 1 | 0 |
_aRobles‐Diaz, Mercedes _eauthor _91856 |
| 700 | 1 | 0 |
_aAlvarez‐Alvarez, Ismael _eauthor _91857 |
| 700 | 1 | 0 |
_aGerbes, Alexander _eauthor _91858 |
| 700 | 1 | 0 |
_aWeber, Sabine _eauthor _91859 |
| 700 | 1 | 0 |
_aStirnimann, Guido _eauthor _91860 |
| 700 | 1 | 0 |
_aKullak‐Ublick, Gerd _eauthor _91861 |
| 700 | 1 | 0 |
_aCortez‐Pinto, Helena _eauthor _91862 |
| 700 | 1 | 0 |
_aGrove, Jane I. _eauthor _91863 |
| 700 | 1 | 0 |
_aLucena, M. Isabel _eauthor _91864 |
| 700 | 1 | 0 |
_aAndrade, Raul J. _eauthor _91865 |
| 700 | 1 | 0 |
_aAithal, Guruprasad P. _eauthor _91866 |
| 245 | 0 | 0 | _aA new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry |
| 260 |
_bJohn Wiley and Sons Inc., _c2022-08-15. |
||
| 500 | _a/pmc/articles/PMC7614006/ | ||
| 500 | _a/pubmed/35899490 | ||
| 520 | _aBACKGROUND & AIMS: No multi‐national prospective study of drug‐induced liver injury (DILI) has originated in Europe. The design of a prospective European DILI registry, clinical features and short‐term outcomes of the cases and controls is reported. METHODS: Patients with suspected DILI were prospectively enrolled in the United Kingdom, Spain, Germany, Switzerland, Portugal and Iceland, 2016-2021. DILI cases or non‐DILI acute liver injury controls following causality assessment were enrolled. RESULTS: Of 446 adjudicated patients, 246 DILI patients and 100 had acute liver injury due to other aetiologies, mostly autoimmune hepatitis (n = 42) and viral hepatitis (n = 34). DILI patients (mean age 56 years), 57% women, 60% with jaundice and 3.6% had pre‐existing liver disease. DILI cases and non‐DILI acute liver injury controls had similar demographics, clinical features and outcomes. A single agent was implicated in 199 (81%) DILI cases. Amoxicillin‐clavulanate, flucloxacillin, atorvastatin, nivolumab/ipilimumab, infliximab and nitrofurantoin were the most commonly implicated drugs. Multiple conventional medications were implicated in 37 (15%) and 18 cases were caused by herbal and dietary supplements. The most common single causative drug classes were antibacterials (40%) and antineoplastic/immunomodulating agents (27%). Overall, 13 (5.3%) had drug‐induced autoimmune‐like hepatitis due to nitrofurantoin, methyldopa, infliximab, methylprednisolone and minocycline. Only six (2.4%) DILI patients died (50% had liver‐related death), and another six received liver transplantation. CONCLUSIONS: In this first multi‐national European prospective DILI Registry study, antibacterials were the most commonly implicated medications, whereas antineoplastic and immunomodulating agents accounted for higher proportion of DILI than previously described. This European initiative provides an important opportunity to advance the study on DILI. | ||
| 540 | _a© 2022 The Authors. Liver International published by John Wiley & Sons Ltd. | ||
| 540 | _ahttps://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | ||
| 546 | _aen | ||
| 690 |
_aMetabolic & Toxic Liver Diseases _91867 |
||
| 655 | 7 |
_aText _2local |
|
| 786 | 0 | _nLiver Int | |
| 856 | 4 | 1 |
_uhttp://dx.doi.org/10.1111/liv.15378 _zConnect to this object online. |
| 999 |
_c2071 _d2071 |
||